Telescope Innovations Corp · CSE:TELI
Telescope Innovations — Investor Presentation (September 2022)
29 slides from Telescope Innovations's investor presentation, Sep 8, 2022
Slide 1: Fewer Trials. More Discoveries.
FEWER TRIALS. MORE DISCOVERIES.
Slide 2: Disclaimer and forward-looking statements
TELI (CSE) The Presentation is intended for educational and informational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the participants individually. The information is not designed to provide financial, tax planning, acc
Slide 3: Our Company
TELI (CSE) OUR COMPANY TELIF (OTCQB) Telescope Innovations Corp. is a technology company that leverages a unique combination of automation, analytics, and chemical process manufacturing expertise to develop next-generation technology platforms. We deploy these platforms through partnerships to resol
Slide 4: What We Do
TELI (CSE) WHAT WE DO TELESCOPE AUTOMATION TELIF (OTCQB) Building a foundational set of advanced automation tools • Powerful analytics and software • Self-driving laboratories Our core platform • Accelerated research technology breaks down barriers in process TELESCOPE INDUSTRIES Developing and comm
Slide 5: Who We Are
TELI (CSE) WHO WE ARE Our award-winning scientific leadership has collectively authored TELIF (OTCQB) over 450 academic publications and 34 patents. PROF. JASON HEIN PROF. BARRY SHARPLESS PALOMA PRIETO SHAD GRUNERT DR. LARS YUNKER CEO SENIOR ADVISOR VP, OPERATIONS VP, INNOVATION VP, AUTOMATION Leads
Slide 6: Who We Are: Directors
TELI (CSE) WHO WE ARE Our directors bring over 60 years combined experience in building technology companies TELIF (OTCQB) and successfully managing companies in the capital markets. DR. ANDY ROBINSON ROBERT MINTAK ALI PEJMAN PROF. JASON HEIN HENRY DUBINA An experienced scientist with a 20+ years ex
Slide 7: Telescope Automation
TELESCOPE AUTOMATION TELIF (OTCQB) TELI (CSE)
Slide 8: Automation
TELI (CSE) TELESCOPE AUTOMATION We combine robotic automation, online analysis, and machine learning to TELIF (OTCQB) guide chemistry decision-making. = Adaptive automation Quality controls Higher quality data Fewer experiments Fewer trials, and measurements required more discoveries Fully automated
Slide 9: Automation: Traditional R&D versus Telescope Automation
TELI (CSE) TELESCOPE AUTOMATION Traditional R&D is the “blind” search for new processes and chemicals. Finding specific chemical TELIF (OTCQB) pathways requires labour-intensive trial and error. Telescope Automation transforms this approach with more efficient tools and techniques. TRIAL 1 ISOLATION A
Slide 10: Automation: DILC Product Line
TELI (CSE) TELESCOPE AUTOMATION: DILC PRODUCT LINE A game-changing tool to visualize and understand chemical reactions TELIF (OTCQB) Already deployed by five major global pharmaceutical companies Rapid, real-time sampling frequency Comprehensive reaction profiling Compatible with heterogeneous, air- a
Slide 11: Automation: Accomplishments and Paths to Commercialization
TELI (CSE) TELESCOPE AUTOMATION: ACCOMPLISHMENTS AND PATHS TO COMMERCIALIZATION TELIF (OTCQB) Q2 | 2021 Q1 | 2022 Telescope occupies dedicated lab Pfizer contracts Telescope to establish facility in Vancouver, British proof-of-concept work for fully automated Columbia. lab workflows. Q2 | 2022 - 2024
Slide 12: Telescope Industries
TELESCOPE INDUSTRIES TELIF (OTCQB) TELI (CSE)
Slide 13: Industries
TELI (CSE) TELESCOPE INDUSTRIES We apply our technology to enable faster, more reliable TELIF (OTCQB) process scale up. Our current focus is process innovation for the battery materials. Conventional stepwise chemical plants are: Slow to scale Costly to build Generate large amounts of waste CURRENT
Slide 14: Industries: Common Inefficiencies in Chemical Manufacturing
TELI (CSE) TELESCOPE INDUSTRIES: COMMON INEFFICIENCIES IN CHEMICAL MANUFACTURING TELIF (OTCQB) Complicated supply chains High equipment CapEx Large volumes of waste generated Low process efficiency of stepwise batch production telescopeinnovations.com 14
Slide 15: Industries: Tools to Scale Chemical Manufacturing
TELI (CSE) TELESCOPE INDUSTRIES: We utilize our tools to develop and scale chemical manufacturing processes. TELIF (OTCQB) OUR TOOLS THE RESULTS ROBOTICS AND ONLINE FASTER SCALE UP FEWER PROCESS AUTOMATION ANALYSIS STEPS CURRENT FOCUS: Material refinement for batteries CO2 Carbon capture and utilizat
Slide 16: Project Highlight: Lithium Refinement
TELI (CSE) PROJECT HIGHLIGHT: LITHIUM REFINEMENT TELIF (OTCQB) We are optimizing lithium refinement technology in partnership with Standard Lithium . Our improvements enable higher extraction efficiency of low-grade brines. We are also exploring the utilization and sequestration of CO2 within SLI’s pr
Slide 17: Industries: Accomplishments and Paths to Commercialization
TELI (CSE) TELESCOPE INDUSTRIES: ACCOMPLISHMENTS AND PATHS TO COMMERCIALIZATION TELIF (OTCQB) Q2 | 2022 Q4 | 2022 Telescope initiates partnership with Development of industrial carbon Hatch Ltd. for studies of battery dioxide capture and storage materials. projects. 1 2 3 Q3 | 2022 Telescope granted
Slide 18: Telescope Health
HEALTH TELESCOPE TELIF (OTCQB) TELI (CSE)
Slide 19: Health
TELI (CSE) TELESCOPE HEALTH Telescope provides enabling technology and manufacturing TELIF (OTCQB) processes for the pharmaceutical industry. We uncover and develop efficient routes to manufacturing new medicines. CURRENT FOCUS: Novel access to emerging Process optimization for psychedelic markets (P
Slide 20: Health: Barriers to Deployment of Novel Therapeutics
TELI (CSE) TELESCOPE HEALTH Barriers to the large-scale deployment of novel therapeutic compounds: TELIF (OTCQB) AIR SENSITIVITY YIELD TEMP PRESSURE TRIAL# Laborious and time consuming Unsafe reaction routes Complex reaction conditions Variability in reproducibility manufacturing processes telescope
Slide 21: Health: Core Technology for Novel Therapeutics
TELI (CSE) TELESCOPE HEALTH Our core technology accelerates research and paves the way for accessing TELIF (OTCQB) novel therapeutics. Targeted Increased safety therapeutic delivery Reduced Optimized reaction complexity manufacturing process NOVEL, NEXT GENERATION COMPOUNDS telescopeinnovations.com
Slide 22: Health: Accomplishments and Paths to IP Commercialization
TELI (CSE) TELESCOPE HEALTH: ACCOMPLISHMENTS AND PATHS TO IP COMMERCIALIZATION TELIF (OTCQB) Q4 | 2021 Q3 | 2022 Filed non-provisional, PCT patent on Additional patent filings to grow novel manufacturing methods for intellectual property portfolio on scope of psilocybin and related compounds. chemica
Slide 23: Business Case & Shareholder Value Proposition
TELI (CSE) TELIF (OTCQB) BUSINESS CASE & SHAREHOLDER VALUE PROPOSITION
Slide 24: Strategic Partners and Clients
TELI (CSE) STRATEGIC PARTNERS AND CLIENTS TELIF (OTCQB) SCIENTIFIC PHARMACEUTICAL MINING CONSULTING INSTRUMENTATION COMPANIES COMPANIES ENGINEERING COMPANIES COMPANIES telescopeinnovations.com 24
Slide 25: Comparables
TELI (CSE) COMPARABLES TELIF (OTCQB) AUTOMATION INDUSTRIES HEALTH telescopeinnovations.com 26
Slide 26: Business Model
TELI (CSE) BUSINESS MODEL TELIF (OTCQB) IN-HOUSE LICENCE OR SERVICE ONGOING PROTOTYPE SELL IP CONTRACTS CONTRACT REVENUE DEVELOPMENT WITH WITH RETENTION OF PARTNERS IP TO LICENSE / SELL telescopeinnovations.com 28
Slide 27: Strategic Milestones
TELI (CSE) STRATEGIC MILESTONES TELIF (OTCQB) ACCOMPLISHED NEXT 12 MONTHS • Launched DILC product, onboarding units in • Position DILC as industry standard several pharmaceutical companies technology for pharmaceutical R&D AUTOMATION • Completed proof-of-concept work for fully • Establish Telescope
Slide 28: Capitalization
TELI (CSE) CAPITALIZATION TELIF (OTCQB) Telescope Innovations Corp. Capital Structure | May 10, 2022 Price (Ave) Number Shares issued 48,786,070 Stock options $1.49 3,425,000 Warrants $— — Fully Diluted Share Position 52,211,070 Shares held by Directors/Officers – 10,143,741 | 21% telescopeinnovation
Slide 29: Thank You
THANK YOU Contact: [email protected] FEWER TRIALS. MORE DISCOVERIES.
Telescope Innovations — Investor Presentation (September 2022) on 6ix